Related Experiment Video
Updated: May 23, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARP inhibitors during conception and pregnancy in breast cancer
Flora Zagouri1, Meletios-Athanasios Dimopoulos1, Angeliki Andrikopoulou1
1Department of Clinical Therapeutics, Medical School, Athens, National and Kapodistrian University of Athens, 11528, Greece.
Abstract:
Approximately 1 in 10 women diagnosed with breast cancer before the age of 35 carry germline BRCA pathogenic/likely pathogenic variants. Poly (ADP-ribose) polymerase (PARP) inhibitors have been recently approved in the treatment of both early and advanced breast cancer. However, there are no published cases of exposure to PARP inhibitors during pregnancy. Treatment with PARP inhibitors during pregnancy is currently contraindicated and can potentially harm fertility in young women with breast cancer. We here summarize all clinical and preclinical data on the effect of PARP inhibitors on pregnancy, fertility and breast-feeding to provide guidance on their optimal use in women of childbearing potential.
Related Concept Videos
Teratogenicity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

